ITF2357 (Givinostat)

Information	ITF2357 (Givinostat) is an orally active, potent inhibitor of histone deacetylases (HDACs) with IC50 values of 7.5-16 nM.
Targets	histone deacetylases (HDACs)
IC50	7.5 to 16 nM ^[1]
In vitro	In LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduces the release of TNFα, IL-1α, IL-1β, and IFNγ, with IC50 of 10-25 nM, respectively. Using the combination of IL-12 plus IL-18, ITF2357 reduces IFNγ and IL-6 production with IC50 of 12.5-25 nM, independent of decreased IL-1 or TNFα. ^[1] ITF2357 is cytotoxic in multiple myeloma (MM) cell lines (RPMI8226, NCI-H929, JJN3, KMS 11, KMS 12, KMS 18, and KMS 20) and acute myelogenous leukemia (AML) cell lines (HL-60, THP-1, U937, KASUMI, KG-1, and TF-1), with a mean IC50 of 200 nM. ITF2357 activates the intrinsic apoptotic pathway, upregulates p21 and downmodulates Bcl-2 and Mcl-1. ITF2357 inhibits the production of IL-6, VEGF, and IFNγ in mesenchymal stromal cells (MSCs) by 80-95%. ^[2] ITF2357 favors β-cell survival during inflammatory conditions. ITF2357 at concentrations of 25 and 250 nM increases islet cell viability, enhances insulin secretion, inhibits release of MIP-1α and MIP-2, reduces NO production and decreases apoptosis rates. ^[3]
In vivo	ITF2357 (1-10 mg/kg) reduces LPS-induced serum TNFα and IFNγ by more than 50% in mice. Anti-CD3-induced cytokines are not suppressed by ITF2357 in PBMCs in the circulation in mice. In concanavalin-A-induced hepatitis, ITF2357 (1 or 5 mg/kg) significantly reduces liver damage. ^[1] ITF2357 (10 mg/kg) significantly prolongs survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line. ^[2] In a mouse model of closed head injury (CHI), ITF2357 (10 mg/kg) improves neurobehavioral recovery, decreases neuronal degeneration, reduces lesion volume, and induces glial apoptosis. ^[4]
Clinical Trials	A Phase II clinical trial of ITF2357 in active systemic onset juvenile idiopathic arthritis (SOJIA) has been completed.
Features	ITF2357 is an orally active, potent inhibitor of histone deacetylases (HDACs).

Information

ITF2357 (Givinostat) is an orally active, potent inhibitor of histone deacetylases (HDACs) with IC50 values of 7.5-16 nM.

Targets

histone deacetylases (HDACs)

IC50

7.5 to 16 nM ^[1]

In vitro

In LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduces the release of TNFα, IL-1α, IL-1β, and IFNγ, with IC50 of 10-25 nM, respectively. Using the combination of IL-12 plus IL-18, ITF2357 reduces IFNγ and IL-6 production with IC50 of 12.5-25 nM, independent of decreased IL-1 or TNFα. ^[1] ITF2357 is cytotoxic in multiple myeloma (MM) cell lines (RPMI8226, NCI-H929, JJN3, KMS 11, KMS 12, KMS 18, and KMS 20) and acute myelogenous leukemia (AML) cell lines (HL-60, THP-1, U937, KASUMI, KG-1, and TF-1), with a mean IC50 of 200 nM. ITF2357 activates the intrinsic apoptotic pathway, upregulates p21 and downmodulates Bcl-2 and Mcl-1. ITF2357 inhibits the production of IL-6, VEGF, and IFNγ in mesenchymal stromal cells (MSCs) by 80-95%. ^[2] ITF2357 favors β-cell survival during inflammatory conditions. ITF2357 at concentrations of 25 and 250 nM increases islet cell viability, enhances insulin secretion, inhibits release of MIP-1α and MIP-2, reduces NO production and decreases apoptosis rates. ^[3]

In vivo

ITF2357 (1-10 mg/kg) reduces LPS-induced serum TNFα and IFNγ by more than 50% in mice. Anti-CD3-induced cytokines are not suppressed by ITF2357 in PBMCs in the circulation in mice. In concanavalin-A-induced hepatitis, ITF2357 (1 or 5 mg/kg) significantly reduces liver damage. ^[1] ITF2357 (10 mg/kg) significantly prolongs survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line. ^[2] In a mouse model of closed head injury (CHI), ITF2357 (10 mg/kg) improves neurobehavioral recovery, decreases neuronal degeneration, reduces lesion volume, and induces glial apoptosis. ^[4]

Clinical Trials

A Phase II clinical trial of ITF2357 in active systemic onset juvenile idiopathic arthritis (SOJIA) has been completed.

Features

ITF2357 is an orally active, potent inhibitor of histone deacetylases (HDACs).

Enzymatic Assay for HDAC Inhibitory Activity of Synthetic Compounds	The assay is performed by adding 100 μL substrate (2×10⁵ cpm), 40 μL buffer (50 mM Tris-HCl, pH 8.0, 750 mM NaCl, 5 mM PMSF, 50% glycerol) and 95 μL distilled water to the crude cellular extract (5 μL). ITF2357 (50 μL) is added to test for HDAC inhibition. The mixture is incubated overnight at room temperature and the reaction quenched by adding 50 μL of a solution containing 259 μL 37% HCl and 28 μL acetic acid in 1 mL distilled water. The [³H]acetyl residues released from the substrate are separated by organic extraction with 600 μL of ethyl acetate, 200 μL of the organic phase is added to standard scintillation fluid, and radioactivity is measured by a beta-counter. Inhibition of HDACs is expressed as the concentration inhibiting 50% of the control activity (by comparing the radioactivity of the samples containing inhibitors to that of the control containing cellular crude extract alone).

Cell lines:	peripheral blood mononuclear cells (PBMCs)
Concentrations:	1 nM - 1 μM
Incubation Time:	24 hours
Method:	After washing, the isolated PBMCs are resuspended in RPMI containing 5% FCS at 5×10⁶/mL, added to a 50-mL conical polypropylene tube, and placed at 4 ℃ overnight. The PBMCs are resuspended the next morning and added to a 96-well flat microtiter plate (100 μL per well). ITF2357 is then added for inhibition studies, and the plates are incubated at 37 ℃ for 1 hour, after which the cells are stimulated with LPS or other stimulants in a final volume of 200 μL per well. The supernatants are removed after incubation at 37 ℃ for 24 hours, and frozen at -80 ℃ until assayed for cytokines.

Cell lines:

peripheral blood mononuclear cells (PBMCs)

Concentrations:

1 nM - 1 μM

Incubation Time:

24 hours

Method:

After washing, the isolated PBMCs are resuspended in RPMI containing 5% FCS at 5×10⁶/mL, added to a 50-mL conical polypropylene tube, and placed at 4 ℃ overnight. The PBMCs are resuspended the next morning and added to a 96-well flat microtiter plate (100 μL per well). ITF2357 is then added for inhibition studies, and the plates are incubated at 37 ℃ for 1 hour, after which the cells are stimulated with LPS or other stimulants in a final volume of 200 μL per well. The supernatants are removed after incubation at 37 ℃ for 24 hours, and frozen at -80 ℃ until assayed for cytokines.

Animal Models:	Mice. For LPS induction of serum cytokines: BALB/c; for anti-CD3-induced cytokines: CD1; for concanavalin A (Con A)-induced acute hepatitis: BALB/c or C57Bl6.
Formulation:	Dissolved in water
Dosages:	0.01-50 mg/kg
Administration:	By gavage in 100 μL water.

Animal Models:

Mice. For LPS induction of serum cytokines: BALB/c; for anti-CD3-induced cytokines: CD1; for concanavalin A (Con A)-induced acute hepatitis: BALB/c or C57Bl6.

Formulation:

Dissolved in water

Dosages:

0.01-50 mg/kg

Administration:

By gavage in 100 μL water.

Molecular Weight (WM):	475.97
Formula:	C₂₄H₂₇N₃O₄.HCl.H₂O
CAS No.:	732302-99-7
Synonyms:	N/A

Molecular Weight (WM):

475.97

Formula:

C₂₄H₂₇N₃O₄.HCl.H₂O

CAS No.:

732302-99-7

Synonyms:

N/A

Dissolve in (25°C):	DMSO ≥95mg/mL
	Water ≥2mg/mL
	Ethanol ≥9mg/mL
Storage:	2 years-20°CPowder
	1 week-4°Cin DMSO
	1 month-80°in DMSO

You can order by phone, email or fax

Free Overnight Delivery on all orders over $ 500.

Recommended Products

Biological Activity

Protocol (Only for Reference)

Kinase Assay: [1]

Cell Assay: [1]

Animal Study:[1]

References

Chemical Information

Quality Control & MSDS

Research Area

Related Inhibitors

Secondary Antibodies

Loading Control Antibodies

Recommended Screening Libraries

We have 1 customer reviews of ITF2357 (Givinostat).

Average Customer Review

Our scientific support team are available to answer any questions or queries. Fill out an inquiry form for ITF2357 (Givinostat) for help.

Quality Matters

Check our customer reviews

Free Sample and Reward

Kinase Assay: ^[1]

Cell Assay: ^[1]

Animal Study:^[1]

Our scientific support team are available to answer any questions or queries.
Fill out an inquiry form for ITF2357 (Givinostat) for help.